Teijin Ltd (3401)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013454)
◆英語タイトル:Teijin Ltd (3401) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013454
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.

Teijin Ltd (3401) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Teijin Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat 18
Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 19
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 20
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 21
Licensing Agreements 22
Teijin Enters into Licensing Agreement with Merz Pharma 22
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 23
Teijin Enters into Licensing Agreement with Radius Health 24
Merck Enters into Licensing Agreement with Teijin Pharma 25
Amgen Enters into Licensing Agreement with Teijin Pharma 26
Teijin Pharma Enters into Licensing Agreement with Versartis 27
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 28
Debt Offering 29
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 29
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 30
Acquisition 31
Teijin Acquires 10% Stake In Kyorin For US$197 Million 31
Teijin Ltd – Key Competitors 32
Teijin Ltd – Key Employees 33
Teijin Ltd – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Joint Venture 36
Recent Developments 37
Financial Announcements 37
May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37
Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38
Other Significant Developments 44
Sep 05, 2016: Teijin Publishes Integrated Report 2016 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teijin Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Teijin Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat 18
Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 19
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 20
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 21
Teijin Enters into Licensing Agreement with Merz Pharma 22
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 23
Teijin Enters into Licensing Agreement with Radius Health 24
Merck Enters into Licensing Agreement with Teijin Pharma 25
Amgen Enters into Licensing Agreement with Teijin Pharma 26
Teijin Pharma Enters into Licensing Agreement with Versartis 27
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 28
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 29
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 30
Teijin Acquires 10% Stake In Kyorin For US$197 Million 31
Teijin Ltd, Key Competitors 32
Teijin Ltd, Key Employees 33
Teijin Ltd, Other Locations 34
Teijin Ltd, Subsidiaries 34
Teijin Ltd, Joint Venture 36

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Teijin Ltd (3401)-製薬・医療分野:企業M&A・提携分析(Teijin Ltd (3401) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆